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Abstract 
Background: Donor human milk is increasingly used as alternative to mother’s own 
milk to feed preterm infants, however, it may provide less long-chain 
polyunsaturated fatty acid (LCPUFA), and more oxidised lipids, which may be 
detrimental for preterm infant health and development. Levels have not been 
reported for donor human milk in the U.K. 
Methods: Donor human milk (n=19) from two neonatal units, milk from preterm 
mothers from a neonatal unit (n=10), and term mothers from the community (n=11) 
were analysed for fatty acid, malondialdehyde, 4-hydroxy-2-nonenal, and hexanal 
content. Study registration: NCT03573531 
Results: Donor human milk had significantly lower absolute LCPUFA content compared 
to term milk (P<0.001) and significantly lower omega-3 PUFAs than preterm milk 
(P<0.05), although relative LCPUFA composition did not differ. Exclusive donor 
human milk feeding leads to significantly lower fat (3.7 vs. 6.7 g/d) and LCPUFA 
(DHA: 10.6 vs. 16.8 mg/d; ARA: 17.4 vs. 25.2 mg/d) intake than recommended by 
ESPGHAN, and provides only 17.3% and 43.1% of the in utero accreted ARA and DHA. 
Donor human milk also had the highest proportion of lipid peroxidation. 
Conclusions: This study confirms that donor human milk in the U.K. has 
insufficient levels of LCPUFAs for preterm infants. It demonstrates for the first 
time that donor human milk has the highest level of lipid peroxidation, compared 
to preterm or term milk. This has important implications for preterm infant 
nutrition, as exclusive donor human milk feeding might not be suitable long-term, 
and may contribute to the development of major preterm neonatal morbidities.  
  
Clinical Relevance Statement 
Donor human milk is used to feed preterm infants; however, milk banking practices 
may negatively affect nutritional quality. This study measured for the first time 
fat, long-chain polyunsaturated fatty acid (LCPUFAs), and lipid peroxidation in 
donor human milk in the U.K., and compared them to breast milk from preterm and 
term mothers. The preliminary results reiterate that donor human milk as the sole 
nutritional source for preterm infants provides fat and LCPUFAs significantly 
below ESPGHAN recommendations. Furthermore, lipid peroxidation was significantly 
higher in donor human milk than term breast milk. This may be due to milk banking 
practices, and warrants further study, as it is well known that such peroxidation 
can contribute to neonatal morbidities like necrotising enterocolitis, and 
retinopathy of prematurity. 
  
1. Introduction 
Docosahexaenoic acid (22:6n-3, DHA) and arachidonic acid (20:4n-6, ARA) are 
omega-3 and omega-6 long-chain polyunsaturated fatty acids (LCPUFAs), 
respectively, essential for optimal visual and brain development, and immune 
system function
1
. The last trimester is the period of maximal brain growth, and an 
interrupted maternal-foetal LCPUFA transfer, low adipose tissue reserves, limited 
conversion of LCPUFAs from precursor fatty acids, and low provisions of preformed 
LCPUFAs put preterm infants at an increased risk of ARA and DHA deficiencies
2
. It 
is therefore essential to ensure adequate postnatal provision of LCPUFAs
3
. 
Breast milk (BM) provides ARA and DHA, and BM from mothers of preterm infants has 
higher DHA levels than that of term mothers
4
. However, producing an adequate BM 
supply is three times less likely in preterm mothers
5
, and donor human milk (DHM) 
from a human milk bank is recommended
6
. The use of DHM is growing world-wide due 





. However, human milk banking practices, such as 
prolonged storage at -20°C, thawing in the refrigerator, and frequent container 
changes, may decrease total fat content and LCPUFAs
9
. The LCPUFA content of DHM is 
not well studied, and unknown in the U.K. Variations in LCPUFA content of DHM have 
been shown in the U.S.A. depending on the milk bank location, and levels may fall 
below preterm infant recommendations
10
. DHM in the U.S.A. is pooled from several 
donors
11
, whereas in other countries, including the U.K., it is not pooled
12
. Since 
LCPUFA levels are highly dependent on maternal nutrition, age, length of 
lactation, and genetic variation, non-pooled DHM potentially has greater 
variability in LCPUFA levels
13
.  
LCPUFAs are susceptible to lipid peroxidation
14
 by oxygen radicals. Lipid 
hydroperoxides are primary lipid peroxidation products, which react further to 
form secondary lipid peroxidation products. Malondialdehyde (MDA), the unspecific 
peroxidation product of PUFAs with more than two double bonds, as well as 4-
hydroxy-2-nonenal (HNE), the specific peroxidation product of omega-6 PUFAs, and 
hexanal, have been identified in BM
15
. Milk banking practices, such as storage and 
processing conditions, can increase lipid peroxidation
9
. Preterm infants are prone 
to oxygen radical associated diseases, such as necrotising enterocolitis (NEC), 
bronchopulmonary dysplasia and retinopathy of prematurity
16
, which may be 
exacerbated by intake of lipid peroxidation products
17
.  
The aims of this study are to quantify for the first time absolute and relative 
LCPUFA content of BM from milk banks provided to neonatal units in the U.K., and 
compare these values with BM from mothers of preterm and term infants. MDA, HNE 
and hexanal levels were also measured to explore whether DHM is a source of lipid 
peroxidation products.   
2. Material and Methods 
2.1. Ethics, participants, and samples 
This cross sectional two-centre study was performed in the U.K. between December 
2018 and February 2019 (www.ClinicalTrials.gov: NCT03573531). The protocol was 
approved by London-South East Research Ethics Committee (reference 18/LO/1330). 
5 mL of unused, bedside DHM was collected in two neonatal units, served by two 
human milk banks, but as DHM is anonymised informed consent could not be obtained 
from donors. DHM in the U.K. is always from only one donor (non-pooled), Holder 
pasteurised, and frozen at -20°C for a maximum of six months from expression
12
. 
Preterm BM (5 mL) was collected at a neonatal unit, and term BM (5 mL) from the 
community. Eligible participants were 18 years, healthy, and delivered either 
before or after 37 weeks gestation for preterm and term BM samples, respectively. 
Exclusion criteria were not understanding study information in English, clinical 
chorioamnionitis or sepsis, smoking (including e-cigarettes), mastitis, or 
receiving treatment for (chronic) infection or inflammatory disease. Participants 
gave informed consent and the study was conducted according to the Declaration of 
Helsinki. A sample size of 10/20 per group was chosen as pragmatic approach, 
considering outcome measurements. After collection, samples were frozen at -70°C 
until analysis, which was within three months. 
2.2. Quantification of fatty acids and total fat content 
Lipids were extracted and analysed as described previously
2
. Briefly, tricosanoic 
acid was added as internal standard to homogenised BM and fatty acids analysed by 
gas chromatography with flame ionisation detector (Agilent Technologies, 7820A). 
Since BM contains 98% triacylglycerols
18
, the sum of the absolute fatty acid 
values was used to estimate total fat content.  
2.3. Quantification of MDA 
MDA was analysed using a thiobarbiturc acid reactive substances assay (Cayman 
Chemical) following manufacturer’s instructions. Samples were incubated with 
trichloric acid and colour reagent and absorbance measured in duplicates at 
540 nm. All samples were analysed on the same plate. Absolute MDA levels were 
adjusted according to previously determined recovery rate of 36.44% (unpublished 
data), and corrected for estimated total fat content, as fat content differed 
significantly between samples and may influence MDA concentrations. 
2.4. Quantification of HNE 
HNE adducts were quantified using OxiSelect HNE Adduct competitive ELISA Kit (Cell 
Biolabs, Inc.) following manufacturer’s instructions. After coating the plate 
overnight, samples were added and incubated, before adding anti-HNE antibody. 
After secondary antibody incubation absorbance was measured at 450 nm, and samples 
measured on the same plate. HNE adducts may depend on protein content; however, no 
significant differences were detected using Bradford Reagent, and no correction 
was performed. Values were corrected for estimated total fat content. Nine samples 
(six DHM, one preterm BM, two term BM) were above the limit of quantification 
(LoQ) (200 µg/mL); whereas 12 samples (six DHM, two preterm BM, four term BM) were 
below LoQ (1.56 µg/mL). To remove potential bias in the results, values above and 
below LoQ were set at the upper and lower LoQ, respectively, as recommended
19
.  
2.5. Quantification of Hexanal 
Hexanal was measured using solid phase micro-extraction (SPME)
20
. BM was 
homogenised and 25% NaCl (w/v) added. After equilibration, headspace volatiles 
were sampled using a polydimethylsiloxane fiber (100 µm, Supelco) before injection 
into a gas chromatograph with flame ionisation detector (Agilent Technologies, 
7820A) fitted with a merlin micro seal, SPME liner, and J&W HP-5 column. Hexanal 
peak area was corrected for percentage recovery based on fat content, as 
suggested
20
, and adjusted for estimated total fat content.  
2.6. Statistical analysis 
Data is reported according to STROBE guidelines
21
. There was one missing value for 
hexanal in the DHM group, due to limited sample volume. Grubbs’ test was used to 
detect significant outliers, which were excluded. Statistical analysis was 
performed using GraphPad Prism (Version 5.0). Data was tested for normality. 
Participant demographics where compared using a t-test. Pump expression was 
compared using Fisher’s exact test. All other values were compared by One-Way 
ANOVA with Tukey’s multiple comparisons test comparing all groups or Kruskal-
Wallis test with Dunn’s multiple comparisons test comparing all columns. For 
correlations, Spearman correlation was used.  
Enteral fat, PUFA, and protein supply was calculated for hypothetical 30
+6
 week 
gestational age infant, weighing 1400 g and receiving full enteral feeding (150 
mL/kg/day), and compared to European Society for Paediatric Gastroenterology, 
Hepatology and Nutrition (ESPGHAN) recommended intake levels
22
 using a one sample 
t-test and compared between the groups using t-test or Mann Whitney test. LCPUFAs 
available for accretion were also calculated for this hypothetical infant as 
described previously
2
, and compared to estimated accretion rates
23
 by one sample t-
test. For comparisons between groups, t-test or Mann Whitney test was used. Data 
presented as mean ± SD, and considered statistically significant at P<0.05. 
* indicates P<0.05, ** and *** P-values <0.01 and <0.001, respectively.  
3. Results  
3.1. Participant and sample characteristics 
40 samples were collected: 19 DHM, 10 preterm and 11 term BM samples (Figure 1). 
Most DHM samples (n = 15; 79%) were collected at St. George’s University Hospitals 
NHS Foundation Trust, and the remaining at Poole Hospital NHS Foundation Trust, 
thse hospitals are served by two different human milk banks. DHM was pasteurised 
within three months of expression (81 ± 18.8 days), and stored for an average of 
177 ± 5.6 days. 
Preterm and term BM donor characteristics are shown in Table S1; DHM donor 
characteristics cannot be reported, due to anonymization. There was no statistical 
difference between preterm and term BM donors’ age (33.1 ± 5.8 vs. 29.5 ± 5.6 
years). Infants of preterm BM donors were significantly younger than infants of 
term BM donors (1.6 ± 1.4 vs. 5.6 ± 3.4 months; P=0.0026), and there was a 






3.2. BM fat content and composition 
Estimated total fat content differed between the groups (P<0.0001). DHM had the 
lowest levels (1.74 ± 0.52 g/100 mL), followed by preterm BM (2.44 ± 
0.65 g/100 mL), with both significantly lower than term BM (4.79 ± 1.60 g/100 mL; 
both P<0.001). 
Levels of fatty acids expressed as percentage of total fatty acids are shown in 
Table S2. There were no significant differences in total saturated fatty acids 
(SFA) or monounsaturated fatty acids (MUFAs), or total omega-3 and omega-6 PUFAs. 
ARA was significantly higher in preterm than term BM (+0.11%; P<0.05), and preterm 
BM DHA was significant higher than both DHM and term BM (+0.24% P<0.01, and +0.22% 
P<0.05, respectively). 20:3n-6, 22:4n-6, and docosapentaenoic acid (22:5n-3, 
DPAn-3) were also significantly higher in preterm than term BM, and 
eicosapentaenoic acid (20:5n-3, EPA), and DPAn-3 were also significantly higher in 
preterm BM than DHM. 
In contrast to percentage composition, absolute total SFAs and MUFAs, and total 
omega-3 and omega-6 PUFAs were significantly lower in DHM than term BM (all 
P<0.001), Table 1. For individual fatty acids, all except 22:4n-6 were 
significantly lower in DHM than term BM. Total omega-3 PUFAs were significantly 
lower (P<0.05) in DHM than preterm BM. 18:3n-6, 20:3n-6, ARA, and 22:4n-6 were 
significantly lower in DHM than preterm BM, although total omega-6 PUFA content 
was not significantly different. Total SFAs and MUFAs, and total omega-6 PUFAs, 
but not total omega-3 PUFAs, were significantly lower in preterm than term BM. DHM 
had the lowest ARA, which was significantly lower than preterm and term BM (-6.24 
mg/100 mL and -11.16 mg/100 mL; P<0.01 and P<0.001, respectively). DHA was 
significantly lower in DHM than preterm and term BM (-9.95 mg/100 mL 
and -13.69 mg/100 mL; P<0.05 and P<0.001, respectively). 
3.3. Estimated PUFA and protein intake from DHM and preterm BM  
Preterm infants in this study were born at 30
+6
 weeks gestational age, and to 
provide an estimate of potential daily enteral fat, PUFA, and protein intake from 
DHM and preterm BM, values were calculated for a hypothetical preterm infant of 
1400 g bodyweight assuming full enteral feeding (210 mL), and values were compared 
to ESPGHAN recommendations
22
. DHM provided significantly lower fat than 
recommended by ESPGHAN (3.67 ± 1.06 g/d vs. 6.72 g/d; P<0.0001), whereas preterm 
BM achieved recommended levels (6.0 ± 2.92 g/d). Daily fat intake from preterm BM 
was significantly higher than from DHM (+2.33 g/d; P=0.0095). Similarly, DHM 
levels of LA, ALA, ARA, and DHA were all significantly below ESPGHAN 
recommendations (Table 2). Preterm BM levels were above the minimum 
recommendations, with DHA significantly above, although still below the upper 
daily limit (42 mg).  
Feeding an infant exclusively DHM for seven days would result in ARA and DHA 
deficits of 55.05 and 43.29 mg/week, respectively, compared to ESPGHAN 
recommendations. Whereas feeding exclusively preterm BM would provide 
significantly more ARA (+97.1 mg/week; P=0.0012) and DHA (+141.07 mg/week; 
P=0.0048), and achieve recommendations
22
. 
DHM and preterm BM provide protein levels significantly below the ESPGHAN 
recommendations (1.96 ± 0.41 g/d and 2.46 ± 0.71 g/d vs. 4.9 g/d; both P<0.0001). 
Exclusive DHM or preterm BM for seven days results in deficits of 20.58 and 
17.08 g/week protein, respectively. Protein intake from DHM is significantly below 
preterm BM (-0.5 g/d; P=0.0293). 
3.4. Estimated LCPUFAs available for accretion 
ARA and DHA available for accretion from DHM and preterm BM were calculated for 
the hypothetical infant. Full enteral feeding with DHM or preterm BM provides 
51.44 ± 4.80 and 62.68 ± 11.25 mg/d of ARA, respectively, significantly below 
estimated in utero accretion rates
23
 of 296.8 mg/d, by 82.7% and 78.9%, 
respectively (both P<0.0001). After one week of exclusively DHM or preterm BM 
feeding deficits of 1717.53 mg and 1638.12 mg, respectively, occur, with ARA 
significantly higher in preterm BM than DHM (P=0.0012). DHA from DHM and preterm 
BM was also significantly below estimated in utero accretion rate (25.97 ± 3.62 
and 41.77 ± 13.28 mg/d, at 43.13% and 69.38% of in utero accretion of 60.2 mg/d; 
P<0.0001 and P=0.0024, respectively), producing deficits of 239.64 mg or 129.03 mg 
after seven days of full enteral feeding with DHM or preterm BM, respectively. DHA 
availability is significantly higher from preterm BM than DHM (P=0.0048).  
3.5. Lipid peroxidation 
3.5.1. MDA 
Uncorrected MDA content was different between groups (Figure 2A). DHM levels were 
significantly lower than preterm BM (38.83 ± 11.05 µM vs. 55.32 ± 16.54 µM; 
P<0.05), but not than term BM (51.27 ± 19.66 µM). MDA is derived from PUFAs, and 
MDA content was therefore corrected for estimated fat content (Figure 2B). After 
correction for total fat, MDA concentration remained significantly different 
between groups (P=0.0248); with both DHM and preterm BM levels significantly 
higher than term BM (23.46 ± 6.28 µM vs. 9.12 ± 2.66 µM, and 21.53 ± 6.83 µM vs. 
9.12 ± 2.66 µM, respectively, both P<0.001).  
3.5.2. HNE 
HNE content did not differ significantly between groups (Figure 3A). When HNE was 
corrected for fat content, a significant difference was seen (P=0.0482; Figure 
3B). DHM was significant higher than term BM (59.99 ± 75.13 µg/mL vs. 8.18 ± 13.14 
µg/mL; P<0.05). Preterm BM was not significantly different from the other groups. 
3.5.3. Hexanal 
There was a significant difference in hexanal between groups (P=0.0091; Figure 
4A). DHM was significantly higher than preterm BM (124.5 ± 90.86 mm
2
 vs. 34.43 ± 
32.85 mm
2
; P<0.05), but not term BM. Following correction for fat, there were 
significant difference between groups (P=0.0009; Figure 4B). DHM levels were 
significantly higher than both preterm and term BM (67.68 ± 52.40 mm
2
 vs. 16.12 ± 
19.58 mm
2
 and 9.47 ± 6.41 mm
2
, respectively, both P<0.01).  
3.5.4. Correlations of ARA and DHA with lipid peroxidation products 
Absolute ARA and DHA were correlated with uncorrected MDA and hexanal, and ARA 
with uncorrected HNE content. There were significant positive correlations between 
both ARA and DHA and MDA (r=0.4700; P=0.0025, and r=0.3587; P=0.0249, 
respectively). There was no significant correlation between DHA and hexanal or ARA 
and hexanal and HNE.   
4. Discussion and conclusion 
This study investigated the LCPUFA and lipid peroxidation product content of DHM 
provided to two neonatal units in the U.K, and compared these values to preterm 
and term BM. Significantly lower fat, absolute ARA and DHA and increased lipid 
peroxidation product levels were identified in DHM, which can have important 
clinical implications for preterm infant nutrition and health outcomes.  
The relative fatty acid percentage composition was consistent with reported values 
in the U.K.
24
, and was not significantly different between DHM and term BM, 
suggesting milk banking practices do not affect levels. Similarly, a recent 
systematic review reported the fatty acid composition of DHM is not negatively 
influenced by milk banking processes
25
. However, when expressing fatty acids in 
absolute levels, significantly lower SFAs and MUFAs, and omega-3 and omega-6 PUFAs 
were found in DHM compared to term BM. This dissonance supports the recommendation 
that both relative and absolute fatty acid composition data should be reported
26
.  
Preterm BM had higher DHA than term BM, consistent with previous observations
4
. If 
maternal BM is unavailable, DHM is the recommended alternative
6
. However, 
significantly lower relative DHA and absolute ARA and DHA were found in DHM 
compared to preterm BM. Based on the estimated intake of a 1400 g infant this 
would lead to intake significantly below ESPGHAN recommendations, consistent with 
analyses of DHM in the U.S.A.
27
. ESPGHAN recommendations consider LA and ALA 




DHM and preterm BM were also estimated to provide ARA and DHA significantly below 
in utero accretion rates
23
. These deficits are of particular concern for preterm 
infants, where neurological development and immune system function are 
underdeveloped
3
. Low ARA and DHA intake are also associated with morbidities of 
prematurity, such as NEC, bronchopulmonary dysplasia, retinopathy of prematurity, 
and white matter injury
28
. DHM and maternal BM can be fortified with commercial 
fortifiers. However, in the U.K., currently only bovine BM fortifiers for preterm 
infants are available. Of these, one contains no source of fat and is therefore 
not a source of LCPUFAs, whereas the other one contains LA, ALA, and DHA, but not 
ARA. This study strongly supports the use of a commercial fortifier providing both 
DHA and ARA. However, fortified BM will still provide LCPUFA levels below 
calculated in utero accretion rates, as also described by Harris and Baack
3
. When 
BM is expressed for donation, or expressed by mothers for their preterm infants, 
strategies to increase the overall fat content, such as hind milk expression, may 
also be helpful, since hind milk contains a higher fat content
29
.  
When controlling for the overall fat content of the different milk, significantly 
higher levels of MDA, HNE and hexanal were identified in DHM compared to term BM. 
This study cannot identify if milk banking practices contributed to these higher 
levels, although these practices have the potential to increase lipid 
peroxidation. For example, storage at 4°C increases HNE and MDA, storage at -20°C 
for 60 days increases MDA, and storage at -18°C for three months increases 
hexanal
9




The highest proportion of lipid peroxidation products was identified in DHM. More 
research is needed to define safe upper intake levels for lipid peroxidation 
products. However, studies suggest ingesting lipid peroxidation products increases 
inflammation, potentially via activation of the nuclear factor B signalling 
pathway
17
. Repeated intake of lipid peroxidation products has been shown to be 
carcinogenic, and associated with growth retardation, intestinal and 
cardiovascular diseases. The latest European Medicines Agency recommendation 
(EMA/PRAC/347675/2019) is to protect parenteral lipid solutions from light to 
avoid adverse outcomes in neonates due to toxic lipid degradation products, and a 
similar strategy should be used for DHM. Endogenous antioxidants in BM may provide 




This is the first study to quantify relative and absolute LCPUFAs and lipid 
peroxidation in DHM, preterm and term BM in the U.K. DHM levels were measured at 
one time-point, and not over the journey from expression to administration, so the 
role of milk banking practices can only be inferred. It cannot be discounted that 
donor BM had low fat and LCPUFAs to begin with. Therefore, further research is 
needed to confirm our findings and clarify the relative contribution of milk 
banking to the observed differences between DHM and term BM. In the meantime, we 
have provided recommendations for human milk banking practices to maximise the 
LCPUFA levels and maintain nutritional quality of DHM
9
.  
A strength of the study is that DHM was measured from samples provided by two 
neonatal units, served by two different human milk banks, giving a clinically 
relevant perspective rather than mimicking processes in the laboratory. However, 
these were samples of surplus rather than fresh DHM, as DHM is rare in the U.K. 
and provision to the infant has priority. The study also used a range of endpoints 
to measure lipid peroxidation, providing a more complete assessment. A limitation 
is that the effects of milk banking practices on LCPUFAs and lipid peroxidation 
products can only be inferred; however, the results provide novel information on 
the actual levels of LCPUFAs and lipid peroxidation products in DHM that would 
have been provided to preterm infants. 
In conclusion, the results suggest DHM has lower LCPUFA and higher lipid 
peroxidation than preterm or term milk. Estimated LCPUFA intake provided by DHM is 
significantly below ESPGHAN recommendations and far below foetal accretion rates. 
This implies that DHM is not suitable long-term as sole diet for preterm infants, 
and should be used in conjunction with preterm BM wherever possible. The lower 
LCPUFA and higher lipid peroxidation product levels may be due to milk banking 
practices. These results have important implications internationally, as milk 
banking guidelines and practices are often mirrored across countries. In addition, 
higher lipid peroxidation levels in DHM may leave preterm infants more vulnerable 
to common comorbidities. These results highlight a need for further research to 
confirm our findings and explore interventions to increase and protect LCPUFAs in 
DHM and minimise lipid peroxidation. 
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Figure 1: Participant flow through the study  
Preterm BM samples were collected at the Neonatal Unit at St. George’s University Hospitals 
NHS Foundation Trust, and term BM samples from the community at Bournemouth University. 
 
Figure 2: Absolute MDA concentration of DHM, preterm and term BM (A) and corrected for fat 
content (B) 
 
Figure 3: Absolute HNE concentration of DHM, preterm and term BM (A) and corrected for fat 
content (B) 
 
Figure 4: Absolute hexanal concentration of DHM, preterm and term BM (A) and corrected for 
fat content (B) 
  
Table 1: Absolute fatty acid composition of DHM, preterm and term BM  
 
* significant different to DHM, 
# 







DHM Preterm BM Term BM P-value 
10:0 26.53 ± 9.09
###
 38.19 ± 11.81
###
 78.05 ± 29.55*** <0.0001 
12:0 112.0 ± 41.09
###
 179.8 ± 65.90* 
###
 315.20 ± 96.89*** <0.0001 
14:0 115.1 ± 37.23
###
 239.1 ± 125.9** 310.3 ± 111.1*** <0.0001 
16:0 378.5 ± 119.2
###
 498.8 ± 152.2
###
 1154 ± 585.1*** <0.0001 
18:0 152.6 ± 103.3
###
 217.5 ± 130.6
#
 462.8 ± 296.1*** 0.0005 
20:0 2.03 ± 1.36
##
 3.07 ± 1.87 5.29 ± 3.50** 0.0024 
 SFAs 809.5 ± 293.2
###
 1145 ± 341.2
###
 2198 ± 822.7*** <0.0001 
16:1n-7 40.28 ± 13.49
###
 65.49 ± 26.86
##
 126.5 ± 64.87*** <0.0001 
18:1n-7/n-9 610.5 ± 173.7
###
 910.2 ± 367.0
###
 1831 ± 699.9*** <0.0001 
20:1n-9 9.47 ± 2.97
###
 14.41 ± 4.43
##
 34.15 ± 23.29*** <0.0001 
24:1n-9 1.32 ± 0.55
###
 1.25 ± 0.69
###
 2.97 ± 1.45*** <0.0001 
 MUFAs 664.2 ± 190.7
###
 993.8 ± 396.8
###
 2004 ± 756.5*** <0.0001 
18:2n-6 (LA) 223.6 ± 65.04
###
 308.6 ± 93.81
###
 587.1 ± 214.1*** <0.0001 
18:3n-6 2.26 ± 0.69
###
 3.36 ± 1.10* 
###
 6.80 ± 1.70*** <0.0001 
20:3n-6 6.95 ± 2.26
###
 11.45 ± 5.06* 14.20 ± 4.40*** <0.0001 
20:4n-6 (ARA) 8.26 ± 2.90
###
 14.86 ± 6.97** 19.78 ± 5.97*** <0.0001 
22:4n-6 1.87 ± 1.05 3.53 ± 2.09* 3.24 ± 1.34 0.0087 
 Omega-6 PUFAs 243.0 ± 70.95
###
 340.9 ± 100.5
###
 631.0 ± 224.2*** <0.0001 
18:3n-3 (ALA) 22.28 ± 9.49
###
 39.66 ± 28.81 68.93 ± 24.21*** 0.0003 
20:5n-3 (EPA) 1.10 ± 0.48
###
 3.26 ± 2.76* 4.58 ± 2.80*** 0.0003 
22:5n-3 (DPAn-3) 2.85 ± 1.37
###
 6.49 ± 4.00* 9.38 ± 6.07*** 0.0001 
22:6n-3 (DHA) 4.70 ± 1.67
###
 14.65 ± 8.50* 18.39 ± 14.34*** 0.0005 
 Omega-3 PUFAs 31.39 ± 12.41
###










Table 2: Absolute fatty acid composition of DHM, preterm and term BM  
 
* significant different to DHM, 
# 





DHM Preterm BM Term BM P-value 
10:0 26.53 ± 9.09
###
 38.19 ± 11.81
###
 78.05 ± 29.55*** <0.0001 
12:0 112.0 ± 41.09
###
 179.8 ± 65.90* 
###
 315.20 ± 96.89*** <0.0001 
14:0 115.1 ± 37.23
###
 239.1 ± 125.9** 310.3 ± 111.1*** <0.0001 
16:0 378.5 ± 119.2
###
 498.8 ± 152.2
###
 1154 ± 585.1*** <0.0001 
18:0 152.6 ± 103.3
###
 217.5 ± 130.6
#
 462.8 ± 296.1*** 0.0005 
20:0 2.03 ± 1.36
##
 3.07 ± 1.87 5.29 ± 3.50** 0.0024 
 SFAs 809.5 ± 293.2
###
 1145 ± 341.2
###
 2198 ± 822.7*** <0.0001 
16:1n-7 40.28 ± 13.49
###
 65.49 ± 26.86
##
 126.5 ± 64.87*** <0.0001 
18:1n-7/n-9 610.5 ± 173.7
###
 910.2 ± 367.0
###
 1831 ± 699.9*** <0.0001 
20:1n-9 9.47 ± 2.97
###
 14.41 ± 4.43
##
 34.15 ± 23.29*** <0.0001 
24:1n-9 1.32 ± 0.55
###
 1.25 ± 0.69
###
 2.97 ± 1.45*** <0.0001 
 MUFAs 664.2 ± 190.7
###
 993.8 ± 396.8
###
 2004 ± 756.5*** <0.0001 
18:2n-6 (LA) 223.6 ± 65.04
###
 308.6 ± 93.81
###
 587.1 ± 214.1*** <0.0001 
18:3n-6 2.26 ± 0.69
###
 3.36 ± 1.10* 
###
 6.80 ± 1.70*** <0.0001 
20:3n-6 6.95 ± 2.26
###
 11.45 ± 5.06* 14.20 ± 4.40*** <0.0001 
20:4n-6 (ARA) 8.26 ± 2.90
###
 14.86 ± 6.97** 19.78 ± 5.97*** <0.0001 
22:4n-6 1.87 ± 1.05 3.53 ± 2.09* 3.24 ± 1.34 0.0087 
 Omega-6 PUFAs 243.0 ± 70.95
###
 340.9 ± 100.5
###
 631.0 ± 224.2*** <0.0001 
18:3n-3 (ALA) 22.28 ± 9.49
###
 39.66 ± 28.81 68.93 ± 24.21*** 0.0003 
20:5n-3 (EPA) 1.10 ± 0.48
###
 3.26 ± 2.76* 4.58 ± 2.80*** 0.0003 
22:5n-3 (DPAn-3) 2.85 ± 1.37
###
 6.49 ± 4.00* 9.38 ± 6.07*** 0.0001 
22:6n-3 (DHA) 4.70 ± 1.67
###
 14.65 ± 8.50* 18.39 ± 14.34*** 0.0005 
 Omega-3 PUFAs 31.39 ± 12.41
###
 64.07 ± 40.67* 97.21 ± 38.59*** 0.0001 















18:2n-6 (LA) 469.6 ± 132.94* 737.1 ± 319.76 539 
18:3n-3 (ALA) 46.79 ± 19.4*** 83.29 ± 57.4 77 
20:4n-6 (ARA) 17.36 ± 5.92*** 31.20 ± 13.88 25.2 
22:6n-3 (DHA) 10.62 ± 4.62*** 30.77 ± 16.94* 16.8 
